New coumarin-piperazine derivatives alleviate inflammatory bowel diseases as IL-6 inhibitors by targeting NF-κB pathway
This study demonstrates that newly synthesized coumarin-piperazine derivatives, particularly compound 4s, effectively alleviate inflammatory bowel disease by inhibiting the NF-κB pathway to reduce IL-6 expression, thereby mitigating intestinal inflammation with low toxicity.